Kodiak Sciences: Tackling the Global Blindness Threat

Kodiak Sciences is developing innovative biologics for the treatment of serious retinal diseases leading to blindness, such as wet age-related macular degeneration and diabetic retinopathy. The business model is based on the proprietary ABC platform, which allows for significantly longer injection intervals (up to six months) in the eye, thus greatly reducing the burden on patients. As a late-stage biotech company, Kodiak has not yet generated any operational revenue, but successful BLA approval from the FDA could provide access to a lucrative...